Likewise, in gastric cancer, an AI-based model was designed to evaluate HER2-negative regions (0 and 1+), HER2-positive regions (2+ and 3+), and regions with no tumor at all with 69.9% precision [45]. This evidence concerns the gene ERBB2 and gastric cancer.